Last update 20 Mar 2025

IGFBP-2 DNA plasmid vaccine(Fred Hutchinson Cancer Research Center)

Overview

Basic Info

Drug Type
DNA vaccine, Therapeutic vaccine
Synonyms
Target
IGFBP2
Action
modulators
Mechanism
IGFBP2 modulators(IGF binding protein-2 modulators)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases
Active Indication
Ovarian Cancer
Inactive Indication-
Originator Organization
Fred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research Center
Active Organization
University of Washington BothellUniversity of Washington BothellFred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research Center
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with IGFBP-2 DNA plasmid vaccine(Fred Hutchinson Cancer Research Center)
NCT01322802
/ CompletedPhase 1IIT
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer
100 Clinical Results associated with IGFBP-2 DNA plasmid vaccine(Fred Hutchinson Cancer Research Center)
Login to view more data
100 Translational Medicine associated with IGFBP-2 DNA plasmid vaccine(Fred Hutchinson Cancer Research Center)
Login to view more data
100 Patents (Medical) associated with IGFBP-2 DNA plasmid vaccine(Fred Hutchinson Cancer Research Center)
Login to view more data
100 Deals associated with IGFBP-2 DNA plasmid vaccine(Fred Hutchinson Cancer Research Center)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 2-
Fred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research Center
-
Ovarian CancerPhase 2-
University of Washington BothellUniversity of Washington Bothell
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01322802 (ASCO 12016 | ASCO 22016)
ManualManual
Phase 1
Ovarian Cancer
25
(dadoivzoul) = Fatigue (12%) and injection site reactions (12%) kkjaimbaam (zbeywfvttr )
Positive
06 Jun 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free